Cusabio Polyclonal Antibodies
CCND3 Antibody | CSB-PA004814ESR2HU
- SKU:
- CSB-PA004814ESR2HU
- Availability:
- 3 to 7 Working Days
Description
CCND3 Antibody | CSB-PA004814ESR2HU | Cusabio
CCND3 Antibody is Available at Gentaur Genprice with the fastest delivery.
Online Order Payment is possible or send quotation to info@gentaur.com.
Product Type: Polyclonal Antibody
Target Names: CCND3
Aliases: G1/S-specific cyclin-D3, CCND3
Background: Regulatory component of the cyclin D3-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G1/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G1 phase. Hypophosphorylates RB1 in early G1 phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also substrate for SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent manner and repressing its transcriptional activity. Component of the ternary complex, cyclin D3/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex.
Isotype: IgG
Conjugate: Non-conjugated
Clonality: Polyclonal
Uniport ID: P30281
Host Species: Rabbit
Species Reactivity: Human
Immunogen: Recombinant Human G1/S-specific cyclin-D3 protein (1-292AA)
Immunogen Species: Human
Applications: ELISA, WB, IHC, IF, IP
Tested Applications: ELISA, WB, IHC, IF, IP; Recommended dilution: WB:1:500-1:2000, IHC:1:20-1:200, IF:1:50-1:200, IP:1:200-1:2000
Purification Method: Antigen Affinity Purified
Dilution Ratio1: ELISA:1:2000-1:10000
Dilution Ratio2: WB:1:500-1:2000
Dilution Ratio3: IHC:1:20-1:200
Dilution Ratio4: IF:1:50-1:200
Dilution Ratio5: IP:1:200-1:2000
Dilution Ratio6:
Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
Form: Liquid
Storage: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Initial Research Areas: Others
Research Areas: Others